SEARCH OUR PRODUCT CATALOG

MKRN1-BRAF Fusion FISH Probe

The MKRN1-BRAF Fusion FISH Probe is used to confirm a fusion of the MKRN1 and BRAF genes. The fusion of the MKRN1 and BRAF genes has been associated with Thyroid Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.

** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.

Turnaround Time: 7-10 Business Days    Shipping Time: 1-2 Day Expedited Shipping

SKU Test Kits Buffer Dye Color Order Now
MKRN1-BRAF-20-ORGR  (Standard Design) 20 (40 μL) 200 μL
MKRN1-BRAF-20-RERE 20 (40 μL) 200 μL
MKRN1-BRAF-20-REOR 20 (40 μL) 200 μL
MKRN1-BRAF-20-REGO 20 (40 μL) 200 μL
MKRN1-BRAF-20-REGR 20 (40 μL) 200 μL
MKRN1-BRAF-20-REAQ 20 (40 μL) 200 μL
MKRN1-BRAF-20-ORRE 20 (40 μL) 200 μL
MKRN1-BRAF-20-OROR 20 (40 μL) 200 μL
MKRN1-BRAF-20-ORGO 20 (40 μL) 200 μL
MKRN1-BRAF-20-ORAQ 20 (40 μL) 200 μL
MKRN1-BRAF-20-GORE 20 (40 μL) 200 μL
MKRN1-BRAF-20-GOOR 20 (40 μL) 200 μL
MKRN1-BRAF-20-GOGO 20 (40 μL) 200 μL
MKRN1-BRAF-20-GOGR 20 (40 μL) 200 μL
MKRN1-BRAF-20-GOAQ 20 (40 μL) 200 μL
MKRN1-BRAF-20-GRRE 20 (40 μL) 200 μL
MKRN1-BRAF-20-GROR 20 (40 μL) 200 μL
MKRN1-BRAF-20-GRGO 20 (40 μL) 200 μL
MKRN1-BRAF-20-GRGR 20 (40 μL) 200 μL
MKRN1-BRAF-20-GRAQ 20 (40 μL) 200 μL
MKRN1-BRAF-20-AQRE 20 (40 μL) 200 μL
MKRN1-BRAF-20-AQOR 20 (40 μL) 200 μL
MKRN1-BRAF-20-AQGO 20 (40 μL) 200 μL
MKRN1-BRAF-20-AQGR 20 (40 μL) 200 μL
MKRN1-BRAF-20-AQAQ 20 (40 μL) 200 μL

BRAF Gene Summary

This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]

Gene Name: B-Raf Proto-oncogene, Serine/threonine Kinase

Chromosome: CHR7: 140433812 -140624564

Locus: 7q34

MKRN1 Gene Summary

This gene encodes a protein that belongs to a novel class of zinc finger proteins. The encoded protein functions as a transcriptional co-regulator, and as an E3 ubiquitin ligase that promotes the ubiquitination and proteasomal degradation of target proteins. The protein encoded by this gene is thought to regulate RNA polymerase II-catalyzed transcription. Substrates for this protein's E3 ubiquitin ligase activity include the capsid protein of the West Nile virus and the catalytic subunit of the telomerase ribonucleoprotein. This protein controls cell cycle arrest and apoptosis by regulating p21, a cell cycle regulator, and the tumor suppressor protein p53. Pseudogenes of this gene are present on chromosomes 1, 3, 9, 12 and 20, and on the X chromosome. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Apr 2014]

Gene Name: Makorin Ring Finger Protein 1

Chromosome: CHR7: 140152839 -140179369

Locus: 7q34

Gene Diseases

The MKRN1 BRAF Fusion has been associated with the following diseases:

Disease Name
Thyroid Carcinoma

FISH Probe Protocols

Protocol, Procedure, or Form Name Last Modified Download

A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms

BRAF rearrangements are found in about 20% of acinar-type neoplasms, and may serve as a potential treatment target. This study examined the efficacy of FISH versus NGS for detecting BRAF translocations in 31 acinar-type neoplasms. As part of FISH analysis, our BRAF break apart probes were used to detect BRAF rearrangements. The team found that, compared to NGS, FISH was highly sensitive, specific, and time- and cost-effective.

Alternative lengthening of telomeres, ATRX loss and H3_K27M mutations in histologically defined pilocytic astrocytoma with anaplasia

Pilocytic astrocytoma (PA) is a type of brain tumor. Certain molecular abnormalities can be indicative of PA such as alternative lengthening of telomeres or loss of ATRX. In many cases of PA, there is a duplication in the kinase domain of the BRAF gene called KIAA1549_BRAF. Red and green FISH probes were used to identify this BRAF gene duplication. The duplication was found to be present in 31% of the PA patients.

Atypical Spitzoid Neoplasms in Childhood: A Molecular and Outcome Study

Atypical spitzoid neoplasms (APNs) are primarily pediatric lesions characterized by their intermediate features; clinically and histopathologically, they fall somewhere between benign spitz nevi and malignant melanoma. The genetics of these tumors are still poorly understood. In this study, 34 APNs were analyzed using FISH and IHC. Our ALK, BRAF, and NTRK1 break-apart FISH probes were used to detect rearrangements of the genes .

Genomic Profiling of Primary Histiocytic Sarcoma Reveals Two Molecular Subgroups

Histiocytic sarcoma (HS) is a rare, aggressive cancer that can occur in the GI tract, skin and liver. This study analyzed 21 cases of HS using RNA sequencing, whole exome sequencing, and FISH. BAC FISH probes from Empire Genomics were used to detect NF1 (RP11-14206) and PTNP11 (RP11-748H13, RP11-9P8, RP11-90F3, RP11-660M3), while BRAF translocations were identified using our BRAF break-apart probe. The team found many abnormalities within the RAS-RAF-MAPK pathway in all 21 cases, with aberrations in NF1 (6/21), MAP2K1 (5/21), PTPN11 (4/21), BRAF (4/21), KRAS (4/21), NRAS (1/21) and LZTR1 (1/21).